Compare Invesco Ltd. (IVZ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Twist Bioscience Corp — how do they compare? Invesco Ltd. trades at $31.56 (market cap $13.85B), while Twist Bioscience Corp trades at $124.23 (market cap $7.72B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.74% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| IVZ | TWST | |
|---|---|---|
Market Cap | $13.85B | $7.72B |
Sector | Financials | Health |
52-Week High | $32.01 | $124.88 |
52-Week Low | $20.67 | $24.16 |
Enterprise Value | $24.01B | $7.65B |
Dividend Yield | 2.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $31.52, down 0.69% today, near its consensus price target of $32.50. The stock shows a bullish technical signal with moving averages supporting an uptrend, while recent earnings have been mixed with Q2 2026 beating expectations. Revenue grew to $6.38 billion in 2025, though net income was negative. Analyst sentiment is balanced with 12 buy and 16 hold ratings, and the company maintains a stable dividend.
The outlook for IVZ hinges on sustained asset under management growth and expense control to return to profitability. Key risks include market volatility affecting AUM and competitive pressures. Upside potential exists if operational improvements continue, but investors face uncertainty from inconsistent earnings performance.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
